We appreciate the comments from Vyas et al. (1) Although our study demonstrated that prediction of infants' immunoprophylaxis failure (IF) is possible in early pregnancy, whether women with extremely high viral load require earlier antiviral treatment for prevention of IF remains unknown.(2) Two randomized controlled trials showed no cases of IF (0/239) after the use of tenofovir disoproxil fumarate (TDF) in women with baseline HBV DNA >5.3log IU/ml in the third trimester.